X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (72937) 72937
Book Review (11816) 11816
Publication (5189) 5189
Newsletter (994) 994
Book Chapter (487) 487
Newspaper Article (233) 233
Conference Proceeding (230) 230
Magazine Article (179) 179
Dissertation (102) 102
Book / eBook (28) 28
Trade Publication Article (21) 21
Paper (12) 12
Web Resource (12) 12
Government Document (9) 9
Data Set (8) 8
Reference (5) 5
Journal / eJournal (3) 3
Presentation (1) 1
Report (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (58787) 58787
humans (40455) 40455
male (22707) 22707
animals (20823) 20823
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (16428) 16428
female (16393) 16393
middle aged (11665) 11665
statins (11321) 11321
biochemistry & molecular biology (11084) 11084
aged (9804) 9804
pharmacology & pharmacy (9149) 9149
rats (8196) 8196
risk factors (6769) 6769
cholesterol (6699) 6699
adult (6623) 6623
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (6196) 6196
abridged index medicus (5934) 5934
cardiac & cardiovascular systems (5746) 5746
analysis (5583) 5583
enzymes (5475) 5475
mice (5406) 5406
oxidative stress (5170) 5170
treatment outcome (5139) 5139
simvastatin (5081) 5081
research (5063) 5063
reductase (4423) 4423
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (4171) 4171
atorvastatin (4136) 4136
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (4086) 4086
proteins (4034) 4034
expression (3953) 3953
physiological aspects (3904) 3904
medicine, general & internal (3854) 3854
risk (3694) 3694
cell biology (3658) 3658
kinetics (3612) 3612
metabolism (3599) 3599
peripheral vascular disease (3576) 3576
prevention (3570) 3570
atherosclerosis (3524) 3524
cholesterol, ldl - blood (3523) 3523
endocrinology & metabolism (3506) 3506
dose-response relationship, drug (3505) 3505
enzyme inhibitors - pharmacology (3307) 3307
time factors (3247) 3247
therapy (3244) 3244
cancer (3184) 3184
pravastatin (3167) 3167
atorvastatin calcium (3119) 3119
article (3114) 3114
hypercholesterolemia - drug therapy (3071) 3071
oxidation-reduction (2975) 2975
lipids (2932) 2932
oncology (2919) 2919
drug therapy (2864) 2864
care and treatment (2835) 2835
aged, 80 and over (2803) 2803
cardiovascular diseases - prevention & control (2789) 2789
health aspects (2760) 2760
chemistry, medicinal (2756) 2756
aldose reductase (2747) 2747
cardiovascular disease (2729) 2729
apoptosis (2709) 2709
cells, cultured (2656) 2656
in-vitro (2633) 2633
mortality (2628) 2628
gene expression (2617) 2617
biophysics (2554) 2554
disease (2530) 2530
hydroxymethylglutaryl-coa reductase inhibitors (2521) 2521
diabetes (2518) 2518
anticholesteremic agents - therapeutic use (2514) 2514
coronary-heart-disease (2511) 2511
coa reductase inhibitors (2496) 2496
plant sciences (2486) 2486
inhibitors (2446) 2446
inflammation (2427) 2427
hmg-coa reductase (2426) 2426
statin (2422) 2422
hypercholesterolemia (2417) 2417
inhibition (2383) 2383
cells (2360) 2360
cholesterol - blood (2355) 2355
drug therapy, combination (2298) 2298
molecular sequence data (2247) 2247
escherichia-coli (2231) 2231
dihydrofolate reductase (2197) 2197
medicine (2117) 2117
retrospective studies (2076) 2076
microbiology (2056) 2056
research article (2043) 2043
aldehyde reductase - antagonists & inhibitors (2038) 2038
myocardial-infarction (2036) 2036
rats, sprague-dawley (2034) 2034
antioxidants (2026) 2026
amino acid sequence (2018) 2018
multidisciplinary sciences (2013) 2013
cardiovascular (2004) 2004
cardiovascular-disease (1960) 1960
toxicology (1959) 1959
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (21) 21
Online Resources - Online (11) 11
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Chemistry (A D Allen) - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (71502) 71502
German (611) 611
Japanese (486) 486
French (475) 475
Spanish (370) 370
Russian (316) 316
Chinese (224) 224
Italian (129) 129
Polish (96) 96
Korean (93) 93
Portuguese (83) 83
Hungarian (75) 75
Czech (55) 55
Dutch (53) 53
Swedish (45) 45
Turkish (39) 39
Danish (28) 28
Finnish (25) 25
Norwegian (22) 22
Croatian (17) 17
Ukrainian (15) 15
Hebrew (10) 10
Serbian (10) 10
Bulgarian (7) 7
Romanian (7) 7
Slovenian (5) 5
Slovak (4) 4
Bosnian (3) 3
Lithuanian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9798, pp. 1231 - 1243
Summary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary... 
Internal Medicine | STROKE | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | THERAPY | MYOCARDIAL-INFARCTION | AVAILABILITY | HEART-FAILURE | SELF-REPORT | ACUTE CORONARY SYNDROMES | MEDICINES | VALIDITY | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Data Collection | Secondary Prevention | Stroke - drug therapy | Urban Population | Antihypertensive Agents - therapeutic use | Drug Utilization | Cardiovascular Agents - therapeutic use | Developed Countries | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Rural Population | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Coronary Disease - drug therapy | Adult | Female | Aged | Developing Countries | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Care and treatment | Research | Cardiovascular diseases | Health aspects | Cardiovascular agents | Studies | Low income groups | Stroke | Households | Socioeconomic factors | Data collection | Cardiovascular disease | Epidemiology | Economic development | Community | Drug use | Index Medicus | Abridged Index Medicus | Antihypertensive Agents/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Cardiovascular Agents/therapeutic use | Coronary Disease/drug therapy | Cardiovascular Diseases/prevention & control | Platelet Aggregation Inhibitors/therapeutic use | Stroke/drug therapy | MEDICIN OCH HÄLSOVETENSKAP | Adrenergic beta-Antagonists/therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | MEDICAL AND HEALTH SCIENCES
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2012, Volume 55, Issue 10, pp. 4740 - 4763
Journal Article
2002, ISBN 9783764363079, x, 151
Book
European Journal of Epidemiology, ISSN 0393-2990, 1/2014, Volume 29, Issue 10, pp. 767 - 775
The heterogeneity in case-control studies on the associations between community-acquired pneumonia (CAP) and ACE-inhibitors (ACEi), statins, and proton pump... 
PHARMACO-EPIDEMIOLOGY | Case control studies | Prescription drugs | Pneumonia | Databases | Primary health care | Hospital administration | General practice | Proton pump inhibitors | Medications | Drug prescriptions | Public Health | Medicine & Public Health | Community acquired pneumonia | Case–control | Infectious Diseases | Oncology | Cardiology | Epidemiology | Ace-inhibitors | Statins | Epidemiology methods | Case-control | MORTALITY | PROJECT | METAANALYSIS | BIAS | VALIDATION | ENZYME INSERTION/DELETION POLYMORPHISM | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | THERAPY | DRUGS | COHORT | COMMUNITY-ACQUIRED-PNEUMONIA | Community-Acquired Infections - etiology | Community-Acquired Infections - epidemiology | Humans | Middle Aged | Netherlands - epidemiology | Pneumonia - prevention & control | Male | Case-Control Studies | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aged, 80 and over | Adult | Female | Odds Ratio | Proton Pump Inhibitors - adverse effects | Pneumonia - etiology | Risk Assessment | Pneumonia - epidemiology | Risk Factors | Logistic Models | Treatment Outcome | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Adolescent | Aged | Community-Acquired Infections - prevention & control | Population Surveillance | Bacterial pneumonia | Pharmacy | Risk factors | ACE inhibitors | Antacids | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 18, pp. 1733 - 1745
Adolescents with type 1 diabetes received one of four regimens: angiotensin-converting–enzyme (ACE) inhibitor–placebo, statin–placebo, ACE inhibitor–statin, or... 
INTIMA-MEDIA THICKNESS | C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | INTERVENTION TRIAL ADDIT | CONVERTING-ENZYME-INHIBITOR | GLUCOSE CONTROL | ALBUMIN EXCRETION | HIGH-RISK | MICROALBUMINURIA | YOUNG-PEOPLE | FOLLOW-UP | Albuminuria - etiology | Double-Blind Method | Area Under Curve | Humans | Male | Diabetes Mellitus, Type 1 - complications | Albuminuria - prevention & control | Creatinine - urine | Diabetes Mellitus, Type 1 - urine | Diabetes Mellitus, Type 1 - drug therapy | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Diabetes Mellitus, Type 1 - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Lipids - blood | Adolescent | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Female | Drug Therapy, Combination | Child | Type 1 diabetes | Patient outcomes | Analysis | Outcome and process assessment (Health Care) | Dosage and administration | Drug therapy | ACE inhibitors | Statins | Creatinine | Adolescence | Puberty | Enzymes | C-reactive protein | Diabetes mellitus | Albumin | Triglycerides | Apolipoproteins | Cholesterol | Risk factors | Glomerular filtration rate | Apolipoprotein B | Peptidyl-dipeptidase A | Angiotensin | Teenagers | Diabetes | Cardiovascular diseases | Drug dosages | Age | Endocrinology | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 03/2012, Volume 55, Issue 5, pp. 2311 - 2323
Aldo-keto reductase 1C3 (AKR1C3; type 5 17 beta-hydroxysteroid dehydrogenase) is overexpressed in castration resistant prostate cancer (CRPC) and is implicated... 
TARGET | CHEMISTRY, MEDICINAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PURIFICATION | BIOLOGICAL EVALUATION | AKR1C3 | ABIRATERONE ACETATE | 17-BETA-HSD1 | RESISTANT PROSTATE-CANCER | EXPRESSION | 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE | Antineoplastic Agents - chemical synthesis | Humans | Male | Structure-Activity Relationship | Hydroxyprostaglandin Dehydrogenases - metabolism | Fenamates - pharmacology | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | 20-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | 3-Hydroxysteroid Dehydrogenases - metabolism | Antineoplastic Agents - pharmacology | Prostatic Neoplasms - drug therapy | Fenamates - chemistry | Testosterone - biosynthesis | Cyclooxygenase Inhibitors - chemistry | Antineoplastic Agents - chemistry | Hydroxyprostaglandin Dehydrogenases - genetics | Cyclooxygenase Inhibitors - pharmacology | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Aldo-Keto Reductase Family 1 Member C3 | Testosterone - antagonists & inhibitors | Cyclooxygenase 2 - metabolism | Cyclooxygenase Inhibitors - chemical synthesis | Cell Line, Tumor | Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Fenamates - chemical synthesis | Cyclooxygenase 1 - metabolism | 3-Hydroxysteroid Dehydrogenases - genetics | Isoenzymes - antagonists & inhibitors | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10013, pp. 61 - 69
Summary Background WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible... 
Internal Medicine | Drug Costs | Platelet Aggregation Inhibitors - economics | Cardiovascular Diseases - drug therapy | Humans | Income | Malaysia | Secondary Prevention | Aspirin - supply & distribution | Urban Population | Angiotensin-Converting Enzyme Inhibitors - supply & distribution | Angiotensin-Converting Enzyme Inhibitors - economics | Sweden | Pakistan | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Iran | Rural Population | China | Adrenergic beta-Antagonists - economics | Brazil | Poland | Aspirin - therapeutic use | Aspirin - economics | Chile | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Cardiovascular Agents - economics | Colombia | Argentina | Platelet Aggregation Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | United Arab Emirates | Adrenergic beta-Antagonists - supply & distribution | India | Pharmacies | Canada | Cardiovascular Agents - supply & distribution | Cardiovascular Agents - therapeutic use | Bangladesh | Family Characteristics | Developed Countries | Turkey | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | South Africa | Zimbabwe | Developing Countries | Drugs | Prevention | Usage | Cardiovascular diseases | Analysis | Disease prevention | Cardiovascular disease | Costs | Health care access | Preventive medicine | Health risk assessment | Index Medicus | Abridged Index Medicus | Klinisk medicin | Clinical Medicine
Journal Article